Infections

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Substance Related Disorders

Symptoms and General Pathology

Rare Diseases

Mycoses

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Mycosis Fungoides

Lymphoma, T-Cell, Cutaneous

Drug-Related Side Effects and Adverse Reactions

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Bacterial Infections

Communicable Diseases

Bacterial Infections and Mycoses

Lymphosarcoma

Peripheral T-cell Lymphoma

Cutaneous T-cell Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Mechlorethamine

Alkylating Agents

Antineoplastic Agents, Alkylating

Patients are treated with Chlormethine gel (CL) gel. In case of any skin drug reaction, allergic test will be carried out. Patients not allergic to CL gel will continue at reduced application frequency, with the addition of topical steroid if necessary.

Gel to be applied to all skin areas affected by MF-CTCL

chlormethine gel

Julia Scarisbrick, MD

Emmanuella Guenova, MD

Adult patients with early stage MF-CTCL (stage IA-IB) will be eligible for this study. A total of 100 early stage MF-CTCL patients diagnosed in the past year will be enrolled.

Treatment with CL gel will be applied once daily to all skin areas affected by MF-CTCL and, for 8 weeks, one selected skin area unaffected by MF-CTCL (0.5% body surface area) until treatment response (complete response), study treatment duration completed (56 weeks), progression, or another withdrawal criterion is met.

Depending on the type of skin drug-related reaction (if any) occurring after application of CL gel, this study will categorize patients into three different groups corresponding to three different treatment patterns:

* Group A: Patients with no skin drug reaction with CL gel application
* Group B: Patients developing a skin drug reaction of any grade with CL gel application, not due to allergic reaction to CL gel, will continue treatment at reduced application frequency
* Group C: Patients from Group B unable to tolerate reduced CL gel application frequency will apply a potent topical steroid twice daily in addition to CL gel applied every other day

REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)

Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)

The response status - complete response (CR), partial response (PR), stable disease (SD) and disease progression (PD) - will be assessed using the global response assessment: skin, lymph nodes (not involved at entry), viscera (not involved at entry) and blood (absolute value CD4+CD7- and CD4+CD26- circulating population) as per EORTC-ISCL-USCLC guidelines

European Organisation for Research and Treatment of Cancer - EORTC

Syndrome

Sezary Syndrome

Anti-Infective Agents

Doxycycline

Anti-Bacterial Agents

Antimalarials

Antiprotozoal Agents

Antiparasitic Agents

Doxycycline in either capsules or tablets will be administered at 400mg total per day. Patients will be treated for five months, or up to one year for those with a partial response at 5 months.

Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.

Doxycycline monohydrate

Brian Poligone, M.D. Ph.D.

This study looks at the efficacy of Doxycycline for the treatment of Cutaneous T-cell Lymphomas.

The aim of this study is to evaluate the efficacy of doxycycline in relapsed Cutaneous T-cell Lymphomas (CTCL). The primary objective is to determine the overall response rate of doxycycline monotherapy in patients with relapsed CTCL.

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

Doxycycline in Patients With Relapsed Cutaneous T-cell Lymphoma

Changes in quality of life will be measured throughout the study using questionnaires.

Overall response rate will be determined after five months or a year from initiation of therapy.

Patients who achieve a Partial Response or Complete Response will be monitored for progression up to one year after initiation of therapy.

Rochester General Hospital

Scientist II

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)	NCT04218825	Early Stage Myc...	chlormethine ge...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma	NCT02341209	Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome	Doxycycline mon...	18 Years -	Rochester General Hospital
REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)	NCT04218825	Early Stage Myc...	chlormethine ge...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC

Spots Global Cancer Trial Database for mycosis fungoides (mf)